Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancerBiagio Ricciuti, Jia Luo, Federica Pecci et al.|Annals of Oncology|2022Cited by 100
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLCJoao V. Alessi, Mark M. Awad, Arielle Elkrief et al.|Journal of Thoracic Oncology|2023Cited by 91
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) ConsortiumTalal El Zarif, Danai Dima, Amin H. Nassar et al.|Journal of Clinical Oncology|2023Cited by 69
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysisAntonio D’Alessio, David J. Pinato, Bernardo Stefanini et al.|The Lancet Oncology|2024Cited by 64